Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and co… Read more
Akums Drugs and Pharmaceutical (AKUMS) - Total Assets
Latest total assets as of September 2025: ₹51.59 Billion INR
Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) holds total assets worth ₹51.59 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Akums Drugs and Pharmaceutical - Total Assets Trend (2022–2025)
This chart illustrates how Akums Drugs and Pharmaceutical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Akums Drugs and Pharmaceutical - Asset Composition Analysis
Current Asset Composition (March 2025)
Akums Drugs and Pharmaceutical's total assets of ₹51.59 Billion consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 2.5% |
| Accounts Receivable | ₹7.78 Billion | 18.9% |
| Inventory | ₹6.81 Billion | 16.6% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹83.03 Million | 0.2% |
| Goodwill | ₹20.63 Million | 0.1% |
Asset Composition Trend (2022–2025)
This chart illustrates how Akums Drugs and Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akums Drugs and Pharmaceutical's current assets represent 55.3% of total assets in 2025, a decrease from 61.6% in 2022.
- Cash Position: Cash and equivalents constituted 2.5% of total assets in 2025, up from 1.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 18.9% of total assets.
Akums Drugs and Pharmaceutical Competitors by Total Assets
Key competitors of Akums Drugs and Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Akums Drugs and Pharmaceutical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Akums Drugs and Pharmaceutical generates 0.99x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Akums Drugs and Pharmaceutical generates $8.22 in net profit.
Akums Drugs and Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.95 | 2.13 | 1.48 |
| Quick Ratio | 3.18 | 1.59 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹24.61 Billion | ₹ 13.91 Billion | ₹ 7.29 Billion |
Akums Drugs and Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Akums Drugs and Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 17.0% |
| Total Assets | ₹41.13 Billion |
| Market Capitalization | $123.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Akums Drugs and Pharmaceutical's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Akums Drugs and Pharmaceutical's assets grew by 17.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Akums Drugs and Pharmaceutical (2022–2025)
The table below shows the annual total assets of Akums Drugs and Pharmaceutical from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹41.13 Billion | +16.98% |
| 2024-03-31 | ₹35.16 Billion | +7.65% |
| 2023-03-31 | ₹32.67 Billion | +6.43% |
| 2022-03-31 | ₹30.69 Billion | -- |